



DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Diabetes – Ozempic Drug Quantity Management Policy – Per Days

- Ozempic® (semaglutide subcutaneous injection – Novo Nordisk)

REVIEW DATE: 07/17/2024

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Ozempic, a glucagon-like peptide 1 (GLP-1) agonist, is indicated:¹

- As an adjunct to diet and exercise to improve glycemic control in **adults with type 2 diabetes mellitus.**
- To **reduce the risk of major adverse cardiovascular events** (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

Dosing

The recommended initial dose of Ozempic is 0.25 mg administered as a subcutaneous (SC) injection once weekly (QW) for 4 weeks.¹ The 0.25 mg dose is not effective for glycemic control, but is intended for treatment initiation. Increase from 0.25 mg QW to 0.5 mg QW after 4 weeks. If additional glycemic control is needed after 0.5 mg SC QW for 4 weeks, the dose may be increased to 1 mg SC QW. Similarly, if additional glycemic control is needed after 1 mg SC QW for 4 weeks, the dose may be increased to 2 mg SC QW. The maximum recommended dose is 2 mg SC QW. Ozempic should be administered on the same day each week, without regard to meals. The day of weekly administration may be changed if needed, provided at least 2 days have passed (> 48 hours) since the last dose. If

the patient misses a dose, it should be administered as soon as possible within 5 days after the missed dose. If more than 5 days have passed, the dose should be skipped and administered on the next regularly scheduled day. The regular QW dosing schedule can then be resumed in either case.

Availability

Ozempic is supplied as single-dose pens in the following strengths:¹

- 2 mg/1.5 mL pen (4 doses of 0.25 mg and 2 doses of 0.5 mg OR 4 doses of 0.5 mg) [discontinued]
- 2 mg/1.5 mL pen (2 doses of 1 mg, supplied in cartons of 2 pens) [discontinued]
- 2 mg/3 mL pen (4 doses of 0.25 mg and 2 doses of 0.5 mg OR 4 doses of 0.5 mg)
- 4 mg/3 mL pen (4 doses of 1 mg)
- 8 mg/3 mL pen (4 doses of 2 mg)

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Ozempic. Two quantity limits (Limit A and Limit B) are in place for Ozempic and are outlined below. If the Drug Quantity Management rules are not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Diabetes – Ozempic Drug Quantity Management Policy – Per Days product(s) is(are) covered as medically necessary when the following criteria is(are) met. Any other exception is considered not medically necessary.

Drug Quantity Limit A

Product	Strength and Form	Retail Maximum Quantity Per 28 Days	Home Delivery Maximum Quantity Per 84 Days
Ozempic® (semaglutide SC injection)	0.25 mg and 0.5 mg dose pen (2 mg/1.5 mL) [discontinued]	1.5 mL (1 pen)	4.5 mL (3 pens)
	0.25 mg and 0.5 mg dose pen (2 mg/3 mL)	3 mL (1 pen)	9 mL (3 pens)
	1 mg dose pen (2 mg/1.5 mL) [discontinued]	3 mL (2 pens)	9 mL (6 pens)
	1 mg dose pen (4 mg/3 mL)	3 mL (1 pen)	9 mL (3 pens)
	2 mg dose pen (8 mg/3 mL)	3 mL (1 pen)	9 mL (3 pens)

SC – Subcutaneous.

CRITERIA A

Ozempic (all strengths)

No overrides recommended.

Drug Quantity Limit B

Product	Strength and Form	Retail and Home Delivery Maximum Quantity Per 21 Days
Ozempic® (semaglutide SC injection)	0.25 mg and 0.5 mg dose pen (2 mg/1.5 mL) [discontinued]	ONE claim collectively for ONE GLP-1 agonist or GLP-1/GIP agonist may be approved every 21 days.^o
	0.25 mg and 0.5 mg dose pen (2 mg/3 mL)	
	1 mg dose pen (2 mg/1.5 mL) [discontinued]	
	1 mg dose pen (4 mg/3 mL)	
	2 mg dose pen (8 mg/3 mL)	

SC – Subcutaneous; GLP-1 – Glucagon-like peptide-1; GIP – Glucose-dependent insulinotropic peptide

^o Refer to Appendix A for a list of the drugs included in this limit.

CRITERIA B

Note: The criteria below apply only to Quantity Limit B.

Ozempic 0.25 mg and 0.5 mg dose pen (2 mg/1.5 mL) [discontinued]

1. If the patient is switching from one strength of Ozempic to another strength of Ozempic, approve a one-time override for 1.5 mL (1 pen) at retail or 4.5 mL (3 pens) at home delivery.
2. If the patient is switching from another GLP-1 agonist or GLP-1/GIP agonist to Ozempic, approve a one-time override for 1.5 mL (1 pen) at retail or 4.5 mL (3 pens) at home delivery.

Note: Other GLP-1 agonists and GLP-1/GIP agonists include Adlyxin® (lixisenatide SC injection), Byetta® (exenatide SC injection); Bydureon BCise® (exenatide extended-release SC injection), Mounjaro® (tirzepatide subcutaneous injection), Rybelsus® (semaglutide tablets), Trulicity® (dulaglutide SC injection), liraglutide SC injection (Victoza®, generic), Saxenda® (liraglutide SC injection), Wegovy® (semaglutide SC injection), Zepbound® (tirzepatide SC injection).

Ozempic 0.25 mg and 0.5 mg dose pen (2 mg/3 mL)

1. If the patient is switching from one strength of Ozempic to another strength of Ozempic, approve a one-time override for 3 mL (1 pen) at retail or 9 mL (3 pens) at home delivery.
2. If the patient is switching from another GLP-1 agonist or GLP-1/GIP agonist to Ozempic, approve a one-time override for 3 mL (1 pen) at retail or 9 mL (3 pens) at home delivery.

Note: Other GLP-1 agonists and GLP-1/GIP agonists include Adlyxin[®] (lixisenatide SC injection), Byetta[®] (exenatide SC injection); Bydureon BCise[®] (exenatide extended-release SC injection), Mounjaro[®] (tirzepatide subcutaneous injection), Rybelsus[®] (semaglutide tablets), Trulicity[®] (dulaglutide SC injection), liraglutide SC injection (Victoza[®], generic), Saxenda[®] (liraglutide SC injection), Wegovy[®] (semaglutide SC injection), Zepbound[®] (tirzepatide SC injection).

Ozempic 1 mg dose pen (2 mg/1.5 mL) [discontinued]

1. If the patient is switching from one strength of Ozempic to another strength of Ozempic, approve a one-time override for 3 mL (2 pens) at retail or 9 mL (6 pens) at home delivery.
2. If the patient is switching from another GLP-1 agonist or GLP-1/GIP agonist to Ozempic, approve a one-time override for 3 mL (2 pens) at retail or 9 mL (6 pens) at home delivery.

Note: Other GLP-1 agonists and GLP-1/GIP agonists include Adlyxin[®] (lixisenatide SC injection), Byetta[®] (exenatide SC injection); Bydureon BCise[®] (exenatide extended-release SC injection), Mounjaro[®] (tirzepatide subcutaneous injection), Rybelsus[®] (semaglutide tablets), Trulicity[®] (dulaglutide SC injection), liraglutide SC injection (Victoza[®], generic), Saxenda[®] (liraglutide SC injection), Wegovy[®] (semaglutide SC injection), Zepbound[®] (tirzepatide SC injection).

Ozempic 1 mg dose pen (4 mg/3 mL)

1. If the patient is switching from one strength of Ozempic to another strength of Ozempic, approve a one-time override for 3 mL (1 pen) at retail or 9 mL (3 pens) at home delivery.
2. If the patient is switching from another GLP-1 agonist or GLP-1/GIP agonist to Ozempic, approve a one-time override for 3 mL (1 pen) at retail or 9 mL (3 pens) at home delivery.

Note: Other GLP-1 agonists and GLP-1/GIP agonists include Adlyxin[®] (lixisenatide SC injection), Byetta[®] (exenatide SC injection); Bydureon BCise[®] (exenatide extended-release SC injection), Mounjaro[®] (tirzepatide subcutaneous injection), Rybelsus[®] (semaglutide tablets), Trulicity[®] (dulaglutide SC injection), liraglutide SC injection (Victoza[®], generic), Saxenda[®] (liraglutide SC injection), Wegovy[®] (semaglutide SC injection), Zepbound[®] (tirzepatide SC injection).

Ozempic 2 mg dose pen (8 mg/3 mL)

1. If the patient is switching from one strength of Ozempic to another strength of Ozempic, approve a one-time override for 3 mL (1 pen) at retail or 9 mL (3 pens) at home delivery.
2. If the patient is switching from another GLP-1 agonist or GLP-1/GIP agonist to Ozempic, approve a one-time override for 3 mL (1 pen) at retail or 9 mL (3 pens) at home delivery.

Note: Other GLP-1 agonists and GLP-1/GIP agonists include Adlyxin[®] (lixisenatide SC injection), Byetta[®] (exenatide SC injection); Bydureon BCise[®] (exenatide extended-release SC injection), Mounjaro[®] (tirzepatide subcutaneous injection), Rybelsus[®] (semaglutide tablets), Trulicity[®] (dulaglutide SC injection),

liraglutide SC injection (Victoza[®], generic), Saxenda[®] (liraglutide SC injection), Wegovy[®] (semaglutide SC injection), Zepbound[®] (tirzepatide SC injection).

REFERENCES

1. Ozempic[®] subcutaneous injection [prescribing information]. Plainsboro, NJ: Novo Nordisk; September 2023.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	New policy created to add additional quantity limits to approve ONE claim collectively for ONE glucagon-like peptide-1 (GLP-1) agonist or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonist every 21 days at retail or home delivery. New clinical overrides apply to these limits. Existing "Per Days" quantity limits were not changed and no overrides apply.	07/17/2024

APPENDIX A

Table 1. GLP-1 Agonists and GLP-1/GIP Agonists.

Brand (Generic Name)	Dosage Form
Adlyxin® (lixisenatide SC injection)	10-20 mcg Starter Pack (discontinued) 20 mcg Maintenance Pack (discontinued)
Bydureon® (exenatide extended-release SC injection)	2 mg/0.65 mL pen
Bydureon BCise® (exenatide extended-release SC injection)	2 mg/0.85 mL prefilled auto-injector
Byetta® (exenatide SC injection)	5 mcg/0.02 mL dose pen (1.2 mL) 10 mcg/0.04 mL dose pen (2.4 mL)
Mounjaro® (tirzepatide SC injection)	2.5 mg/0.5 mL pen 5 mg/0.5 mL pen 7.5 mg/0.5 mL pen 10 mg/0.5 mg pen 12.5 mg/0.5 mL pen 15 mg/0.5 mL pen
Ozempic® (semaglutide SC injection)	0.25 mg and 0.5 mg dose pen (2 mg/1.5 mL) [discontinued] 0.25 mg and 0.5 mg dose pen (2 mg/3 mL) 1 mg dose pen (2 mg/1.5 mL) [discontinued] 1 mg dose pen (4 mg/3 mL) 2 mg dose pen (8 mg/3 mL)
Rybelsus® (semaglutide tablets)	3 mg tablet 7 mg tablet 14 mg tablet
Saxenda® (liraglutide SC injection)	18 mg/3 mL pen
Trulicity® (dulaglutide SC injection)	0.75 mg/0.5 mL pen 1.5 mg/0.5 mL pen 3 mg/0.5 mL pen 4.5 mg/0.5 mL pen
Victoza® (liraglutide SC injection, generic)	18 mg/3 mL pen (2-pack) 18 mg/3 mL pen (3-pack)
Wegovy® (semaglutide SC injection)	0.25 mg/0.5 mL pen 0.5 mg/0.5 mL pen 1 mg/0.5 mL pen 1.7 mg/0.75 mL pen 2.4 mg/0.75 mL pen
Zepbound® (tirzepatide SC injection)	2.5 mg/0.5 mL pen 5 mg/0.5 mL pen 7.5 mg/0.5 mL pen 10 mg/0.5 mL pen 12.5 mg/0.5 mL pen 15 mg/0.5 mL pen

GLP – Glucagon-like peptide-1; GIP – Glucose-dependent insulinotropic polypeptide; SC – Subcutaneous.

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.